文献速递胸部肿瘤

美国非小细胞肺癌发病率、患病率、生存与初始治疗的最新估计

Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US.
PubMed 文献 · JAMA Oncol · 2021-01-01

该横断面流行病学分析使用美国癌症登记数据(USCS 2010-2017、SEER-18)估算 NSCLC 的发病、患病、生存与初始治疗。2010-2017 年发病率由 46.4/10 万降至 40.9/10 万,I 期发病上升、IV 期略降;2010-2016 年患病率由 175.3/10 万升至 198.3/10 万;5 年生存为 26.4%。

要点

  • I 期 NSCLC 发病率从 10.8/10 万升至 13.2/10 万,或与偶然结节评估改善有关。
  • I 期单用放疗作为初始治疗的比例从 2010 年 14.7% 升至 2016 年 25.7%。
  • ≥65 岁 IV 期患者最常未接受治疗,比例为 38.3%。

核心结论

  • 2010-2017 年美国 NSCLC 总体发病率下降,但 I 期发病率上升,提示早期检出增加。
  • NSCLC 患病率上升、5 年生存 26.4%,高于既往报告,可能与早检和有效治疗可及有关。
  • ≥65 岁 IV 期 NSCLC 患者中未治疗比例较高(38.3%)。

研究设计与样本

  • 横断面流行病学分析,使用美国癌症登记数据。
  • 发病率来自 USCS 数据库(SEER 与 NPCR 合并,2010-2017)。
  • 分期相关发病率、患病率、生存与初始治疗来自 SEER-18(数据至 2016)。
  • 纳入 18 岁及以上、按 ICD-O-3 形态学编码诊断的 NSCLC 患者。
  • 分析时间为 2020 年 6 月至 2020 年 7 月。

主要发现

  • 总体发病率从 46.4/10 万降至 40.9/10 万;<65 岁从 15.5 降至 13.5,≥65 岁从 259.9 降至 230.0。
  • II 期、IIIA 期、IIIB 期发病率稳定,IV 期从 21.7/10 万略降至 19.6/10 万,I 期从 10.8/10 万升至 13.2/10 万。
  • 2010-2016 年患病率从 175.3/10 万升至 198.3/10 万;年轻患者从 77.5 升至 87.9,老年患者从 825.1 降至 812.4。
  • 期间生存分析显示 26.4% 患者生存 5 年。

关键数值与推荐

  • I 期 NSCLC 以放疗为单一初始治疗的比例从 2010 年 14.7% 升至 2016 年 25.7%。
  • ≥65 岁 IV 期 NSCLC 患者未治疗比例为 38.3%。

临床怎么用

  • 解读美国 NSCLC 流行病学趋势时,应关注 I 期发病率上升与 IV 期略降的分期迁移。
  • 评估老年 IV 期 NSCLC 治疗决策时,需注意 ≥65 岁人群未治疗比例较高这一现状。
  • I 期 NSCLC 初始治疗中单用放疗比例上升,提示局部治疗选择正在变化。

局限性

  • 受数据库发布延迟影响,发病率数据截至 2017 年,其他参数截至 2016 年。
  • 患病率为基于 SEER-18 的全国推算值。
  • 为横断面流行病学分析,未报告因果推断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Updated estimates of non-small cell lung cancer (NSCLC) in the US are needed. OBJECTIVE: To calculate the most recent epidemiologic estimates of NSCLC in the US. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional epidemiological analysis used the most recently released data from US cancer registries. The population-based US Cancer Statistics (USCS) database (2010-2017), comprised of the Surveillance, Epidemiology, and End Results (SEER) program and the National Program of Cancer Registries (NPCR) (collectively, SEER-NPCR) provided the NSCLC incidence estimate. The SEER-18 database provided data for incidence, prevalence, survival, and initial treatment by NSCLC stage. Adults aged 18 years or older diagnosed with NSCLC identified by International Classification of Diseases for Oncology, Third Edition, morphology codes were included. MAIN OUTCOMES AND MEASURES: Annual age-adjusted NSCLC incidence per 100 000 persons; annual prevalence per 100 000 persons; survival rate; initial treatment. Due to database release delays, incidence data were available through 2017, and other parameters through 2016. The analysis was conducted from June 2020 to July 2020. RESULTS: There were 1.28 million new NSCLC cases recorded during 2010 to 2017 in the US (SEER-NPCR: 53% male; 67% ≥ 65 years). From 2010 to 2017, NSCLC incidence per 100 000 decreased from 46.4 to 40.9 overall (age <65 years: 15.5 to 13.5; age ≥65 years: 259.9 to 230.0); the incidence of stage II, IIIA, and IIIB NSCLC was stable, and stage IV decreased slightly from 21.7 to 19.6, whereas stage I incidence increased from 10.8 to 13.2. From 2010 to 2016, NSCLC prevalence per 100 000 increased from 175.3 to 198.3 (nationwide projection of SEER-18); prevalence increased among younger patients (77.5 to 87.9) but decreased among older patients (825.1 to 812.4). Period survival analysis found that 26.4% of patients survived 5 years, which is higher than previously reported. The proportion of stage I NSCLC treated with radiation as single initial treatment rose markedly from 14.7% in 2010 to 25.7% in 2016. Patients with stage IV NSCLC aged 65 years or older were most likely to be untreated (38.3%). CONCLUSIONS AND RELEVANCE: The findings of this cross-sectional epidemiological analysis suggest that the increased incidence of stage I NSCLC at diagnosis likely reflected improved evaluation of incidental nodules. A smaller proportion of patients aged 65 years or older with stage IV NSCLC were treated. Earlier detection and availability of effective treatments may underlie increased overall NSCLC prevalence, and higher than previously reported survival.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Ganti AK, Klein AB, Cotarla I, et al. Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US. JAMA Oncol. 2021. PMID: 34673888. doi:10.1001/jamaoncol.2021.4932

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。